Compliance & EnforcementFalse Claims Act
ArchiveFalse Claims Act
3,592 articles from the Compliance & Enforcement Brief.
Articles
🔒 Members Only · Compliance & Enforcement BriefYou’ve reached the member portion of this brief.Members read the full analysis and the source documents in every Brief, six days a week.
Court Rejects “Tenuous” Connection Between FDCA Regulatory Violations and Claims for Payment
Supreme Court to Review When DOJ May Dismiss Relator Suits
Do Your Diligence: M&A Considerations Following OIG’s Special Fraud Alert on Telemedicine
Eli Lilly Accused of Defrauding Government in $60 Million Qui Tam Suit
Second Circuit Agrees that the Anti-Kickback Statute Does Not Contain a “Corruption” Element
This Retaliation Claim Survived Under State Law, but Not the FCA
Suspect Characteristics Identified under a Telehealth Special Fraud Alert
Organizational Conflicts of Interest – Part 1: A Refresher on OCIs
Pushing Back on Kickbacks: $900 Million Settlement in Biotech False Claims Act Case
Second Circuit: Anti-Kickback Statute Liability Doesn’t Require Corrupt Intent
Court Filing Reveals that DOJ Is Investigating Fintech’s Administration of PPP Loans
DOJ Supporting Appeal of Allergan Sales Ruling over FCA Scienter Standards
Biotronik Anti-Kickback Enforcement Action: Bribery Schemes and Lessons Learned
Seventh Circuit Suggests High Standard Under the FCA Whistleblower Retaliation Provision
Poor Bookkeeping Not Actionable Under FCA
Prosecutors Accuse Eli Lilly of $60 Million Fraud in Drug Price Rebate Calculations
Was the Reason for the Plaintiff’s Firing Pretextual? It Depends on What the Definition of “Is” Is
Two Recent False Claims Act Settlements Highlight the Benefits of Self-Disclosure, Remediation, and Cooperation
One More Time: Are AKS Violations Per Se Material to Healthcare Claims Under the FCA?
Keep reading
